In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.
Författare
Summary, in English
CYP3A metabolic activity varies between individuals and is therefore a possible candidate of influence on the therapeutic outcome of the tyrosine kinase inhibitor imatinib in chronic myeloid leukemia (CML) patients. The aim of this study was to investigate the influence of CYP3A metabolic activity on the plasma concentration and outcome of imatinib in CML patients.
Avdelning/ar
Publiceringsår
2016
Språk
Engelska
Sidor
230-238
Publikation/Tidskrift/Serie
Therapeutic Drug Monitoring
Volym
38
Issue
2
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
Lippincott Williams & Wilkins
Ämne
- Hematology
Status
Published
ISBN/ISSN/Övrigt
- ISSN: 0163-4356